NEPHROLOGY DRUGS MARKET - FIVE TRENDS RESHAPING RENAL CARE IN 2026
For decades, nephrology remained a relatively overlooked area within the pharmaceutical industry, characterized by established therapies such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and dialysis, with limited innovation and attention beyond the specialty. That dynamic is changing rapidly. Over the past two years, kidney disease has moved from a relatively peripheral consideration in pharmaceutical strategies to an area where large pharmaceutical companies are willing to invest billions of dollars to establish a presence. A wave of first-in-class approvals for rare kidney diseases, increasing competition to acquire promising renal pipelines, and growing clinical recognition that kidney disease needs to be addressed within a broader systemic care framework are occurring concurrently. These developments are reinforcing one another and accelerating the strategic importance of nephrology across the pharmaceutical landscape.
Five key themes are emerging through this activity. Cardiovascular, kidney, and metabolic care are increasingly converging into an integrated treatment paradigm; a growing pipeline of targeted therapies is reshaping the management of immune-mediated and genetic kidney diseases; M&A and licensing activity involving renal assets has gained momentum; AI is beginning to support kidney disease screening beyond its traditional role in research; and the geographic distribution of kidney disease, along with the associated commercial opportunity, is evolving. These developments are interconnected rather than occurring in isolation. Collectively, they point to a fundamental transformation of the specialty around a central principle where kidney health cannot be addressed independently of broader systemic health.
FIVE TRENDS RESHAPING NEPHROLOGY, AT A GLANCE
Cardiorenal-Metabolic Convergence
Heart, kidney and metabolic care unite under one clinical guideline
Targeted-Therapy Boom
Mechanism-specific drugs replace one-size-fits-all care in IgAN and genetic CKD
M&A and Licensing Surge
Large pharma buys rather than builds renal pipelines
AI Moves Into Screening
Risk-scoring and detection tools get written into clinical pathways
Geographic Rebalancing
Asia-Pacific and other high-burden markets take center stage
SECTION A: THE CARDIORENAL RESET
For years, cardiologists, endocrinologists, and nephrologists have managed overlapping patient populations through largely separate treatment approaches, with each specialty addressing one component of what is increasingly recognized as an interconnected disease continuum. This began to change formally on June 9, 2026, when the American College of Cardiology, American Heart Association, American Diabetes Association, and American Society of Nephrology jointly published the first guideline dedicated to cardiovascular-kidney-metabolic (CKM) syndrome. Published simultaneously in Circulation and the Journal of the American College of Cardiology, the guideline establishes a four-stage CKM framework and highlights that nearly 90.0% of U.S. adults have at least one CKM risk factor. Around the same period, the European Society of Cardiology advanced dedicated guidance on chronic kidney disease, further reinforcing the integration of kidney health into cardiovascular risk management.
Well, it’s much more realistic. It’s integrative pathophysiology. These organs don’t act in isolation.
Pharmacological innovation has, in some respects, preceded this formal convergence. The FLOW trial, which evaluated once-weekly semaglutide in patients with type 2 diabetes and chronic kidney disease, demonstrated a 24.0% relative reduction in major kidney outcomes, strengthening the evidence for glucagon-like peptide-1 (GLP-1) receptor agonists as an important component of kidney care alongside their established applications in diabetes and obesity. The findings add to the expanding role of sodium-glucose cotransporter-2 (SGLT2) inhibitors, renin-angiotensin system inhibitors, and nonsteroidal mineralocorticoid receptor antagonists in slowing chronic kidney disease progression and reducing cardiovascular risk.
Bayer's finerenone (Kerendia), a leading nonsteroidal mineralocorticoid receptor antagonist, provides a clear commercial illustration of this evolving treatment landscape. Bayer reported Kerendia sales of €829 million for full-year 2025, reflecting strong growth driven by increasing demand, particularly in the United States and China. The company subsequently reported positive Phase III results from the FIND-CKD study in adults with non-diabetic chronic kidney disease, expanding the clinical evidence base for finerenone beyond its established use in chronic kidney disease associated with type 2 diabetes. Together, these developments illustrate how cardiovascular, metabolic, and renal treatment strategies are increasingly converging, creating broader clinical applications and expanding commercial opportunities across the kidney-care ecosystem.
KERENDIA (FINERENONE): REPORTED SALES
Source: Bayer AG quarterly and full-year financial disclosures, 2025–2026.
Nephrology is no longer a category cardiologists and primary-care doctors can afford to ignore. A drug that can show benefit across the heart-kidney-metabolic triad, instead of just one organ, has a real shot at picking up prescribers who used to leave CKD undertreated. Companies whose cardiometabolic drugs can’t point to solid renal data are going to find themselves increasingly boxed out.
SECTION B: THE TARGETED-THERAPY BOOM
If cardiorenal convergence is reshaping the treatment paradigm for mainstream CKD, an equally significant transformation is taking place in the kidney’s rarer immune-mediated diseases, led by IgAN, the most common primary glomerular disease and a major cause of CKD and kidney failure. The U.S. FDA has expanded the IgAN treatment landscape rapidly, with new mechanisms emerging alongside established therapies. Tarpeyo (budesonide) received its initial FDA approval in 2021, followed by Filspari (sparsentan) in 2023; more recently, Fabhalta (iptacopan), Vanrafia (atrasentan), and the first A Proliferation-Inducing Ligand (APRIL)-blocking biologic, Voyxact (sibeprenlimab), have further broadened the therapeutic toolkit. Several late-stage candidates, including povetacicept, atacicept, felzartamab, and zigakibart, remain in clinical development, suggesting that the treatment landscape is likely to continue evolving.
IgA NEPHROPATHY: FIVE MECHANISMS APPROVED IN 28 MONTHS
2023
2024
2024
2025
Source: FDA approval actions, 2023–2026.
Surveys conducted with physicians illustrate the pace of change in clinical practice. Despite the growing number of treatment options, a substantial proportion of patients continue to fall short of the proteinuria targets that nephrologists seek to achieve, sustaining demand for therapies that can deliver deeper and more durable disease control. This expanding opportunity is also reflected in Novartis’ IgAN portfolio, which includes Fabhalta and Vanrafia, both acquired through its 2023 acquisition of Chinook Therapeutics. Together, these developments demonstrate how novel mechanisms in nephrology are increasingly supported by global commercialization strategies once regulatory approval is secured.
We now have agents to target B-cell activation, along with the supportive studies of these agents in IgAN, and the trials show rather dramatic improvements in markers of disease compared with historical outcomes.
The same mechanism-driven approach extends into genetic kidney diseases. Autosomal dominant polycystic kidney disease (ADPKD), for example, already has tolvaptan as an approved disease-modifying therapy, while 2026 has brought renewed momentum to APOL1-mediated kidney disease (AMKD), a genetically defined form of CKD associated with APOL1 risk variants. Maze Therapeutics reported positive Phase II proof-of-concept data for MZE829 in March 2026, with the candidate demonstrating a meaningful reduction in urinary albumin-to-creatinine ratio (uACR) in patients with broad AMKD. Meanwhile, Mineralys Therapeutics continued advancing lorundrostat, an aldosterone synthase inhibitor, following Phase II chronic kidney disease data presented at the American Society of Nephrology (ASN) Kidney Week 2025.
The evolution of IgAN is unlikely to stop with the therapies already approved. A growing pipeline spanning B-cell modulation, complement inhibition, APRIL targeting, and other disease-specific mechanisms points to a broader shift in nephrology: treatment is increasingly moving beyond managing downstream manifestations toward directly targeting the biological pathways driving kidney disease.
NEPHROLOGY PIPELINE: THERAPIES IN LATE-STAGE DEVELOPMENT
| CANDIDATE | SPONSOR | MECHANISM | TARGET DISEASE | STAGE |
|---|---|---|---|---|
| Povetacicept | Vertex | BAFF/APRIL dual inhibitor | IgA nephropathy | Phase 3 (BLA filed) |
| Atacicept | Vera Therapeutics | BAFF/APRIL inhibitor | IgA nephropathy | Phase 3 |
| Zigakibart | Novartis | APRIL inhibitor | IgA nephropathy | Phase 3 |
| Felzartamab | Biogen | CD38-targeting antibody | Multiple kidney diseases | Phase 3 |
| MZE829 | Maze Therapeutics | APOL1 inhibitor | APOL1-mediated kidney disease | Phase 2 |
| Lorundrostat | Mineralys Therapeutics | Aldosterone synthase inhibitor | Hypertension-related CKD | Clinical development |
Source: FDA filings, company disclosures and clinical trial registries, current as of 2026.
Why it matters: Nephrology is following roughly the arc oncology went through a decade ago which is moving away from broad, one-size-fits-all supportive care and toward therapies built around a specific mechanism. That raises the ceiling for anyone with a genuinely novel drug, but it also opens a real gap: diagnosis, genetic testing and biopsy-confirmed staging haven’t caught up with how fast new drugs are clearing the FDA.
SECTION C: THE DEALMAKING ENGINE
Large pharmaceutical companies have largely responded to this opportunity through acquisitions rather than internal development. The clearest example is Biogen’s approximately USD 5.6 billion acquisition of Apellis Pharmaceuticals, announced in March 2026. The transaction added Empaveli (pegcetacoplan), which is approved in three indications, including two rare kidney diseases, while also bringing Apellis’ commercial and nephrology expertise to Biogen. The acquisition is expected to support the launch readiness of felzartamab, a CD38-targeting antibody in Phase III development across multiple kidney diseases. Biogen explicitly highlighted the transaction’s role in accelerating its entry into nephrology and strengthening its commercial capabilities.
We just think that if the clinical trials work out for felzartamab as we hope, we will have a running start into the launch, and we could actually potentially achieve peak sales faster than we would if we were just doing this on our own.
The deal follows Biogen’s 2024 acquisition of Human Immunology Biosciences, through which it gained felzartamab, illustrating how promising nephrology assets can attract successive strategic buyers as they progress through clinical development. Elsewhere, BioMarin’s acquisition of Amicus Therapeutics, completed in April 2026, added Galafold (migalastat) for Fabry disease, although the transaction was primarily focused on expanding BioMarin’s rare-disease portfolio rather than acquiring a dedicated kidney pipeline. Meanwhile, Ipsen’s acquisition of Memo Therapeutics added potravitug, a Phase II monoclonal antibody targeting BK polyomavirus in kidney transplant recipients. The program is being developed for BK polyomavirus-associated nephropathy, an area where there are currently no targeted approved treatments.
Large pharma clearly sees kidney disease as worth building a real, lasting position in, not just an opportunistic add-on. Many of the newest mechanisms such as complement inhibition, APRIL blockade, CD38-targeting, and endothelin antagonism sit with small and mid-cap biotechs, expect the deal pace to stay high and prices to keep climbing for anything with solid, biomarker-backed Phase II or III data.
SECTION D: THE DIAGNOSTICS SHIFT
Chronic kidney disease is still one of medicine’s most underdiagnosed conditions, partly because its two core markers estimated glomerular filtration rate and urine albumin-to-creatinine ratio often aren’t ordered together, even in primary-care patients who are clearly at risk. A growing stack of published research, including a 2026 review in the World Journal of Nephrology, makes the case that AI can help close that gap by pulling together longitudinal, multimodal patient data in a way static risk scores never could. Deep-learning models have already been tested for predicting CKD risk from retinal photographs and scoring glomerular pathology automatically from kidney biopsy images, and in some head-to-head comparisons, neural-network models have outperformed experienced nephrologists at predicting disease onset and dialysis outcomes.
Artificial intelligence approaches using imaging or laboratory-based models can facilitate the early detection and risk stratification of CKD and thereby enable optimal treatment to reduce the burden of the disease.
Commercially, none of this looks like a standalone AI product rather it’s showing up as infrastructure. Digital pathology platforms, risk-scoring tools quietly embedded in primary-care electronic health records, and multi-cancer-style early-detection logic adapted for kidney-specific markers are where the money is actually going. The European Society of Cardiology’s 2026 CKD guideline builds systematic, earlier screening directly into its STAMP framework, a sign that risk-scoring and detection tools are being written into clinical pathways, not left as pilot projects that quietly die.
As AI moves from journal articles into embedded infrastructure, nephrology’s technology partners start to look different. Diagnostics companies, EHR vendors and digital pathology platforms are becoming just as commercially relevant to the renal pipeline as the drugmakers themselves, because every new targeted therapy for IgAN, ADPKD or APOL1-mediated disease only works if patients get identified earlier than current referral patterns allow.
SECTION E: THE GLOBAL SOURCING RESET
Chronic kidney disease tracks closely with diabetes and hypertension, and both are rising fastest outside the traditional U.S. and European core of nephrology drug spending. IgA nephropathy treatment, in particular, is taking off fastest across Asia-Pacific, and China’s Nefecon (the local budesonide formulation) has already found rapid uptake, with a large share of eligible patients started on therapy in a fairly short window after launch. North America still accounts for the bulk of nephrology drug revenue today, but the diagnosed-patient base in Asia-Pacific, the Middle East and other high-growth healthcare markets is expanding faster than in the mature West, a pattern that echoes what’s already playing out in oncology dealmaking.
Compared to European and American populations, China has a large IgAN patient population. Chinese IgAN patients experience more rapid disease progression and poorer prognosis. Therefore, IgAN patients require early diagnosis, and a comprehensive treatment approach that spans early intervention, initial therapy, and maintenance therapy.
That shift cuts both ways. It widens the addressable population for global originators willing to invest in local trials, regulatory pathways and distribution partnerships, the kind of arrangement Travere has built with Renalys Pharma in Japan, or Viatris has built around Nefecon. It also opens doors for regional manufacturers and biosimilar developers, especially around the erythropoiesis-stimulating agents and older antihypertensive drugs that still make up most of nephrology’s prescription volume even as targeted biologics take a growing share of the value.
A nephrology strategy built only around U.S. and European reimbursement is going to miss where patient volume is actually growing. Companies building early regulatory, distribution and real-world-evidence capabilities in Asia-Pacific and other high-burden markets are positioning themselves for the next wave of diagnosed patients, rather than fighting over share in a slower-growing developed-market base.
THE BOTTOM LINE
Nephrology in 2026 isn’t one story, it’s five that keep running into each other. A formal cardiovascular-kidney-metabolic guideline is pulling the kidney into the center of cardiology and endocrinology practice at the same moment an unprecedented run of approvals is turning IgA nephropathy from an overlooked orphan condition into a genuinely competitive market. Large pharma is responding to both the way it has in oncology and immunology before it: by buying rather than building, with Biogen, BioMarin and Ipsen among the recent buyers paying real premiums for renal pipelines. Underneath all of it, AI is quietly getting written into screening guidelines instead of staying a research curiosity, and patient growth keeps shifting toward Asia-Pacific and other high-burden markets.
The thread running through every guideline update, earnings call and acquisition here is the same one the CKM guideline authors were essentially making the case for. Kidney disease can’t be managed as its own isolated specialty anymore. The real question for the next few years is whether diagnosis and screening infrastructure and the health systems built around them can keep up with a drug pipeline moving faster than anything nephrology has seen in a generation. The companies that treat novel-modality development, dealmaking, diagnostics and geographic expansion as one coordinated strategy, instead of five separate workstreams, are the ones likely to set the pace from here.
